Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF) Company recently initiated RENEW Phase 2 trial evaluating the safety, tolerability and efficacy of LTI-03 in IPF AUSTIN, Texas,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference )
Also on site :